Atopic Dermatitis

Diving into Atopic Dermatitis and its Rapidly Expanding Pipeline
January 15, 2022

In this video interview, Peter A. Lio, MD, FAAD, expands on his Winter Clinical Dermatology 2022 presentation, "What's Hot and New in Pediatric Dermatology?" He talks the pipeline, black box warnings, and more on atopic dermatitis treatments.

Highlighting the Molluscum Contagiosum Pipeline
January 15, 2022

In this video, Peter Lio, MD, FAAD, expands on his presentation at the 19th annual Winter Clinical Dermatology Conference by diving into molluscum contagiousum treatment and the potential of cantharidin 0.7% (VP-102; Verrica).

Impact of Itch Sparks New Pipeline Direction
January 07, 2022

Skin sensitivity will be a factor in vehicles for new treatments.

Reviewing Clinical Trial Data for JAK Inhibitors
January 05, 2022

Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.

9 Investigators Receive Grants for Eczema Research
January 05, 2022

The new research will investigate many factors of the skin disease like changes over lifetime, new therapy pathways, and the science behind itch and inflammation.

Safety and Efficacy of JAK Inhibitors
January 03, 2022

Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.

FDA approves Tralokinumab-Idrm for AD
December 28, 2021

Leo Pharma has announced the FDA approval of tralokinumab-Idrm (Adbry; Leo Pharma) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older. Jonathan Silverberg, MD, PhD, MPH, associate professor of Dermatology at George Washington University School of Medicine and Health Sciences, and tralokinumab clinical trial investigator gives his comments on this approval.

An Overview of JAK Inhibitors
December 22, 2021

Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.

Work Smarter to Manage Occupational Dermatoses
December 21, 2021

Factors ranging from demographics to the COVID-19 pandemic are shifting the landscape of occupational dermatoses.

Management of Patients with AD on Dupilumab
December 16, 2021

A recent study investigated practical issues related to the use of dupilumab for atopic dermatitis.